The Astrazeneca vaccine should not be offered to young people between 18 to 30 years old because it can have sequelae with its clots and must be replaced by other vaccines, such as Moderna or Pfizer, including your second dose if they already received the first one. There is an immune problem that raises platelets but they must be investigate further the reasons for this process, which are unknown. It is not known whether it affects men or women more.
But this “course correction” does not imply stop vaccination neither in Great Britain nor in Europe because the benefits of the vaccine “are more important” than “the very rare side effects”, which produces a virus that can lead to death. One of the consequences of Covid is that it can produce un stroke in certain cases.
This was the conclusion that arrived at the European Medicines Agency (EMA) in Amsterdam and shortly thereafter, scientists from MHRA, the British health and medical products regulatory agency, at a special briefing in London on the Oxford-AstraZeneca vaccine.
This vaccine is being boycotted by patients in Europe due to fears of its side effects.
The alternative: Pfizer or Moderna
British 18-29 year olds will be offered an alternative to the Oxford-AstraZeneca vaccine, after 79 people developed blood clots after inoculation, British government scientists have decided. They will suggest to get Pfizer or Modern, depending on availability, and the vaccination site may be further from your home.
A nurse prepares a dose of Moderna’s vaccine. Photo: Reuters
The British Medicines and Health Products Regulatory Agency (MHRA) concluded that there is “a possible link” between the Oxford vaccine and blood clots, “extremely rare and unlikely”, with low platelets. Its origin is unknown.
Younger people are much less likely to die from COVID-1. So the Joint Committee on Vaccination and Immunization (JCVI) has decided that it is safer to recommend that you consider receiving another vaccine. They don’t think they have provisioning issues in the kingdom because they already have Pfizer and Moderna has arrived.
England’s deputy chief medical officer, Professor Jonathan Van-Tam, said the new advice on AstraZeneca is a “course correction” for the UK’s “very successful” vaccine launch. According to Van Tan, for most age groups, the “benefits outweigh the risks” of getting the vaccine.
He said the new advice on the Astrazeneca vaccine will haveto an insignificant impact at the launch of the vaccine in the UK.
Symptoms to watch for
“The recommendation is coming after a total of 79 people in the UK have had blood clots after their first dose of Oxford-AstraZeneca through March 31,” said Dr June Raine, Executive Director of the MHRA. , that authorized the vaccine by AstraZeneca. A total of 51 women and 28 men were affected, of between 18 and 79 years old with these clots.
The UK vaccination committee continues to recommend the AstraZeneca vaccine. Photo: AP
“The risk is four people in a million, “added Dr. Raine.
He said that anyone experiencing the following side effects four days after receiving a dose should seek medical attention. They are: Headaches.
- Punctual bruises or spots beyond the vaccination site.
More than 5.6 million people in the UK are now fully vaccinated against COVID. The JCVI has said that “people of any age who have received the first dose of the Oxford vaccine they should continue to be offered the second dose, ”according to the schedule.
JCVI President Professor Wei Shen Lim stated that “we recommend the preference of one vaccine over another for a group age in particular out of precaution and not serious safety concerns. “He added that people in their early 29s must make a choice. But getting the vaccine it is much safer than not receive it.
“Change of British course”
British professor Van Tam said that it is “quite common for doctors to change their preferences about drugs and vaccines.” He said the NHS will provide “the right vaccine at the right time. But that some people” may have to travel further to get their shots.
He insisted that it remains “vitally important” that people get vaccinated when they are invited to do so.
The UK is currently injecting the Pfizer vaccine as well, with the first doses of the Moderna vaccine delivered this Wednesday in Wales.
The decision of the Joint Committee on Vaccination and Immunization follows a review of the Oxford jab by the Medicines and Health Products Regulatory Agency.
Over the weekend, it was revealed that 30 people who have received the vaccine in the UK have developed a blood clot, out of a total of 18.1 million people who have received it.
The MHRA confirmed that seven of those people had died Until March 24.
In the afternoon this Wednesday, the prime minister Boris Johnson said the government believes the Oxford / AstraZeneca vaccine is “safe.
On a visit to Cornwall he insisted that “the crucial thing for everyone is to hear what scientists, medical experts have to say later today.”
What Europeans Say
From Amsterdam, the European Medicines Agency launched its analysis on the Astrazeneca vaccine and its effects. British vaccine suffers a crisis of confidence in the EU, especially for the campaign of France and Germany suggesting it was not safe.
The European drug regulator said “unusual blood clots” should be listed as a side effect “very rare” of the COVID Oxford-AstraZeneca vaccine.
The European Medicines Agency said it had reached its conclusion after taking into account all the available evidence.
European Union health ministers have been told the announcement would have an “immediate impact on vaccination plans” and “vaccine confidence.”
The announcement came at the same time that UK government advisers indicated that British 18-29 year olds will be offered an alternative to the Oxford-AstraZeneca vaccine when it becomes available.
Less risks, more benefits
The EMA has reminded healthcare professionals and people receiving the vaccine to be aware of the possibility of “very rare cases of blood clots” combined with “low levels of platelets in the blood”, within two weeks post-vaccination.
He said that so far, most of the reported cases have occurred in women under 60.
The EMA finding followed an in-depth review of 86 blood clot cases, 18 of which were fatal, as of March 22 from around 25 million people who had received the vaccine.
However, despite the possible link, the regulator said the reported combination of blood clots and low blood platelets “is very rare.” The overall benefits of the vaccine to prevent COVID-19 “outweigh the risks of side effects.”
The Oxford vaccine is one of four vaccines licensed in the EU to protect against COVID-19.
The EMA says studies show it is effective in preventing coronavirus and also reduces the risk of hospitalization and deaths by COVID-19.
Restrictions on AstraZeneca
There have been concerns about whether the Oxford-AstraZeneca vaccine is suitable for younger age groups, following reports of rare blood clots on the continent. This led several European countries to go back and forth in their own vaccination strategies in recent weeks.
But before the last EMA briefing, France, Germany and the Netherlands they had restricted Since then, the vaccine has been used by older people for fear that younger recipients have a greater potential risk of blood clots.
Earlier this week, the EMA’s chief of vaccine strategy said it was “increasingly difficult” to say that “there is no cause-and-effect relationship” between the injection and “rare cases of unusual blood clots.”
Uncertainty about the Oxford-AstraZeneca dose has been presented as one of the main reasons for the slow vaccination program from Europe, compared to the UK, where the injection has been widely used alongside Pfizer’s. In the vaccinations in France there are hematologists, who check the platelet level of the future vaccinated in their analyzes, to authorize the vaccine.